Blood Res 2018; 53(3):
Published online September 28, 2018
https://doi.org/10.5045/br.2018.53.3.223
© The Korean Society of Hematology
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Correspondence to : Correspondence to Adam M. Greenbaum, M.D. Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N. D5-100, Seattle, WA 98109, USA. agreenba@fredhutch.org
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Bendamustine is a chemotherapeutic agent that has shown broad activity in patients with lymphoid malignancies. It contains both alkylating and nucleoside analog moieties, and thus, is not commonly used for stem cell mobilization due to concerns that it may adversely affect stem cell collection. Here we describe the lymphoma subset of a prospective, non-randomized phase II study of bendamustine, etoposide, and dexamethasone (BED) as a mobilization agent for lymphoid malignancies.
This subset analysis includes diffuse large B-cell lymphoma (N=3), follicular lymphoma (N=1), primary mediastinal B-cell lymphoma (N=1), and NK/T-cell lymphoma (N=1). Patients received bendamustine (120 mg/m2 IV d 1, 2), etoposide (200 mg/m2 IV d 1–3), and dexamethasone (40 mg PO d 1–4) followed by filgrastim (10 mcg/kg/d sc. through collection).
We successfully collected stem cells from all patients, with a median of 7.9×106/kg of body weight (range, 4.4 to 17.3×106/kg) over a median of 1.5 days (range, 1 to 3) of apheresis. All patients who received transplants were engrafted using kinetics that were comparable to those of other mobilization regimens. Three non-hematologic significant adverse events were observed in one patient, and included bacterial sepsis (grade 3), tumor lysis syndrome (grade 3), and disease progression (grade 5).
For non-Hodgkin lymphoma, mobilization with bendamustine is safe and effective.
Keywords Bendamustine, Stem cell mobilization, Non-Hodgkin lymphoma
Blood Res 2018; 53(3): 223-226
Published online September 28, 2018 https://doi.org/10.5045/br.2018.53.3.223
Copyright © The Korean Society of Hematology.
Adam M. Greenbaum1*, Damian J. Green1, Leona A. Holmberg1, Ted Gooley1, Brian G. Till1, Lihua E. Budde2, Heather Rasmussen1, Oliver W. Press1, and Ajay K. Gopal1
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Correspondence to:Correspondence to Adam M. Greenbaum, M.D. Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N. D5-100, Seattle, WA 98109, USA. agreenba@fredhutch.org
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Bendamustine is a chemotherapeutic agent that has shown broad activity in patients with lymphoid malignancies. It contains both alkylating and nucleoside analog moieties, and thus, is not commonly used for stem cell mobilization due to concerns that it may adversely affect stem cell collection. Here we describe the lymphoma subset of a prospective, non-randomized phase II study of bendamustine, etoposide, and dexamethasone (BED) as a mobilization agent for lymphoid malignancies.
This subset analysis includes diffuse large B-cell lymphoma (N=3), follicular lymphoma (N=1), primary mediastinal B-cell lymphoma (N=1), and NK/T-cell lymphoma (N=1). Patients received bendamustine (120 mg/m2 IV d 1, 2), etoposide (200 mg/m2 IV d 1–3), and dexamethasone (40 mg PO d 1–4) followed by filgrastim (10 mcg/kg/d sc. through collection).
We successfully collected stem cells from all patients, with a median of 7.9×106/kg of body weight (range, 4.4 to 17.3×106/kg) over a median of 1.5 days (range, 1 to 3) of apheresis. All patients who received transplants were engrafted using kinetics that were comparable to those of other mobilization regimens. Three non-hematologic significant adverse events were observed in one patient, and included bacterial sepsis (grade 3), tumor lysis syndrome (grade 3), and disease progression (grade 5).
For non-Hodgkin lymphoma, mobilization with bendamustine is safe and effective.
Keywords: Bendamustine, Stem cell mobilization, Non-Hodgkin lymphoma
Abbreviations: PD, progressive disease; PR, partial response..
Gaurav Prakash, Arihant Jain, Kamalkant Sahu, Amanjit Bal, Charanpreet Singh, Rajender Basher, Harmandeep Singh, Kundan Mishra, Aditya Jandial, Deepesh Lad, Alka Khadwal, Radhika Srinivasan, Ashim Das, Neelam Varma, Subhash Varma, Pankaj Malhotra
Blood Res 2021; 56(3): 134-140Nisha Marwah, Manali Satiza, Niti Dalal, Sudhir Atri, Monika Gupta, Sunita Singh, Rajeev Sen
Blood Res 2021; 56(1): 26-30Munira Shabbir-Moosajee, Samad Jehangir, Sobiya Sawani, Tariq Muhammed, Natasha Ali, Usman Sheikh, Salman Adil
Blood Res 2019; 54(2): 108-113